Alexion Pharmaceuticals Incorporated (Nasdaq:ALXN) hit a new 52-week high Friday as it changed hands at $94.53 compared with its previous 52-week high of $93.45. Alexion is currently trading at $94.27 with 155,985 shares changing hands as of 10:46 a.m..
NEW YORK ( TheStreet) -- Alexion Pharmaceuticals Incorporated (Nasdaq: ALXN) hit a new 52-week high Friday as it traded at $94.53 compared with its previous 52-Week high of $93.45. Alexion is changing hands at $94.27 with 155,985 shares traded as of 10:46 a.m. ET. Average volume has been 787,400 shares over the past 30 days. Alexion has a market cap of $8.4 billion and is part of the health care sector and drugs industry. Shares are up 14.7% year to date as of the close of trading on Thursday. Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company has a P/E ratio of 50.6, below the average drugs industry P/E ratio of 88.9 and above the S&P 500 P/E ratio of 23.4. TheStreet Ratings rates Alexion as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Alexion Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center.